MDPI and ACS Style
Koike, H.; Nishida, Y.; Shinomura, T.; Ohkawara, B.; Ohno, K.; Zhuo, L.; Kimata, K.; Ushida, T.; Imagama, S.
Possible Repositioning of an Oral Anti-Osteoporotic Drug, Ipriflavone, for Treatment of Inflammatory Arthritis via Inhibitory Activity of KIAA1199, a Novel Potent Hyaluronidase. Int. J. Mol. Sci. 2022, 23, 4089.
https://doi.org/10.3390/ijms23084089
AMA Style
Koike H, Nishida Y, Shinomura T, Ohkawara B, Ohno K, Zhuo L, Kimata K, Ushida T, Imagama S.
Possible Repositioning of an Oral Anti-Osteoporotic Drug, Ipriflavone, for Treatment of Inflammatory Arthritis via Inhibitory Activity of KIAA1199, a Novel Potent Hyaluronidase. International Journal of Molecular Sciences. 2022; 23(8):4089.
https://doi.org/10.3390/ijms23084089
Chicago/Turabian Style
Koike, Hiroshi, Yoshihiro Nishida, Tamayuki Shinomura, Bisei Ohkawara, Kinji Ohno, Lisheng Zhuo, Koji Kimata, Takahiro Ushida, and Shiro Imagama.
2022. "Possible Repositioning of an Oral Anti-Osteoporotic Drug, Ipriflavone, for Treatment of Inflammatory Arthritis via Inhibitory Activity of KIAA1199, a Novel Potent Hyaluronidase" International Journal of Molecular Sciences 23, no. 8: 4089.
https://doi.org/10.3390/ijms23084089